Home Cardiovascular and Metabolic Genetic Markers Hereditary Hemorrhagic Telangiectasia Genetic Test: ENG, ACVRL1, SMAD4, and Results

Hereditary Hemorrhagic Telangiectasia Genetic Test: ENG, ACVRL1, SMAD4, and Results

By
Vita Library
-
4
Learn how ENG, ACVRL1, and SMAD4 HHT genetic test results guide diagnosis, AVM screening, bleeding care, anemia treatment, family testing, and SMAD4 surveillance.

A hereditary hemorrhagic telangiectasia genetic test looks for a pathogenic variant that disrupts blood-vessel development and maintenance. HHT, also called Osler-Weber-Rendu syndrome, causes telangiectases and larger arteriovenous malformations that connect arteries directly to veins without a normal intervening capillary bed. The most commonly implicated genes are ENG, ACVRL1, and SMAD4. A confirmed molecular diagnosis can be especially valuable in children and younger adults who have not yet developed the full clinical pattern, because serious lung or brain vascular malformations may be present before frequent nosebleeds or visible telangiectases appear. Genetic testing does not show where malformations are located, how large they are, or whether bleeding is active. A positive result therefore starts a structured screening plan rather than completing the evaluation. A negative result is most informative when the family’s disease-causing variant is already known.

  • HHT is usually inherited in an autosomal dominant pattern.
  • ENG, ACVRL1, and SMAD4 account for most genetically confirmed cases.
  • A pathogenic result supports preventive screening for pulmonary, cerebral, hepatic, and other vascular malformations.
  • SMAD4 findings also require juvenile polyposis and gastrointestinal cancer surveillance.
  • A variant of uncertain significance must not be treated as a confirmed HHT diagnosis.

Table of Contents

How HHT Affects Blood Vessels

Normal circulation moves blood from arteries through progressively smaller vessels into capillaries, where oxygen and nutrients are exchanged, and then into veins. In HHT, abnormal signaling during vessel formation can create direct artery-to-vein connections. Small lesions near the skin or mucosal surface are called telangiectases. Larger connections in organs are generally called arteriovenous malformations, or AVMs.

Telangiectases are fragile and can bleed repeatedly. Recurrent spontaneous nosebleeds are the most common early manifestation. They may begin in childhood, become more frequent with age, and range from mild spotting to bleeding severe enough to cause iron-deficiency anemia or require transfusion. Telangiectases can also appear on the lips, tongue, oral cavity, face, fingertips, and gastrointestinal tract.

Pulmonary AVMs allow blood to bypass the filtering function of lung capillaries. This right-to-left shunt can reduce oxygen levels and permit clots, bacteria, or air bubbles to reach the arterial circulation. Potential complications include stroke, transient ischemic attack, and brain abscess, sometimes before a person knows that HHT is present. Many treatable pulmonary AVMs produce few or no symptoms.

Cerebral vascular malformations vary in type and risk. Some remain stable, while others can bleed. Hepatic vascular malformations may create high-flow shunts that place stress on the heart, contribute to high-output cardiac failure, cause pulmonary hypertension, or produce biliary and portal complications. Spinal AVMs are uncommon but can cause neurologic injury.

HHT expression is highly variable, even within one family. One person may have only nosebleeds, while a sibling with the same pathogenic variant has a pulmonary AVM or substantial gastrointestinal bleeding. Age also matters: visible telangiectases and recurrent epistaxis often accumulate over time. This variability is why clinical appearance alone can miss HHT in children and why a genetic diagnosis does not predict an exact course.

HHT is not primarily a clotting-factor disorder. Standard coagulation tests can be normal. The bleeding results from fragile abnormal vessels, and the serious nonbleeding risks arise from shunting through AVMs. Treatment must therefore address the specific site and mechanism rather than assuming that all symptoms have one cause.

ENG, ACVRL1, and SMAD4

ENG encodes endoglin, a protein expressed prominently on vascular endothelial cells. Pathogenic ENG variants cause HHT type 1. People with ENG-related HHT have a relatively high frequency of pulmonary and cerebral AVMs, although any individual may or may not have these features. The gene-phenotype association helps prioritize awareness but does not replace organ screening.

ACVRL1, also known as ALK1, encodes a receptor in the transforming growth factor-beta and bone morphogenetic protein signaling pathway. Pathogenic ACVRL1 variants cause HHT type 2. Hepatic vascular malformations are more frequent in ACVRL1-related disease, and some families have an association with pulmonary arterial hypertension. Pulmonary and cerebral AVMs can still occur, so a result should not be used to omit recommended screening.

SMAD4 transmits signals downstream in the same broader pathway. A pathogenic SMAD4 variant can cause a combined juvenile polyposis-HHT syndrome. Affected people may develop HHT vascular findings as well as hamartomatous gastrointestinal polyps, bleeding, anemia, and increased gastrointestinal cancer risk. Some SMAD4 variant carriers also develop aortic root dilation or other connective-tissue features. Management requires coordination between an HHT team and a hereditary gastrointestinal cancer or polyposis service.

The distinction between SMAD4-related disease and HHT caused by ENG or ACVRL1 is clinically important. Standard HHT screening is still required, but colonoscopy and upper gastrointestinal surveillance must also follow juvenile polyposis recommendations. Removing a bleeding polyp does not address pulmonary or cerebral AVM risk, and treating a nosebleed does not replace cancer surveillance.

A smaller proportion of HHT-like disease is associated with other genes, including GDF2 in some families. In addition, vascular-malformation syndromes caused by genes such as RASA1 or EPHB4 can overlap clinically without being classic HHT. Panel design should reflect the phenotype and the laboratory’s validated scope.

Most pathogenic variants in ENG, ACVRL1, and SMAD4 reduce normal gene function. They include single-nucleotide changes, small insertions or deletions, splice-altering variants, and larger exon or whole-gene deletions. Because no single recurrent variant explains most cases, comprehensive sequencing plus deletion/duplication analysis is usually more informative than testing only a few selected sites.

A gene result provides a diagnosis and inheritance explanation but only limited prediction of severity. Clinical decisions should not assume that all ENG carriers will have a pulmonary AVM or that all ACVRL1 carriers will develop liver complications. Every confirmed or strongly suspected patient needs a systematic evaluation based on current HHT guidance.

Clinical Diagnosis and Who Should Be Tested

The Curaçao criteria are widely used to assess a clinical diagnosis. The four criteria are recurrent spontaneous nosebleeds; multiple telangiectases at characteristic sites; visceral involvement such as pulmonary, cerebral, hepatic, spinal, or gastrointestinal vascular malformations; and a first-degree relative with HHT according to these criteria. Three or four criteria indicate definite HHT, two indicate possible or suspected HHT, and zero or one makes HHT less likely.

These criteria are most reliable in adults. A child with a pathogenic familial variant may have none of the visible features yet still be at risk for a silent pulmonary or brain AVM. A young person should not be declared unaffected only because nosebleeds and telangiectases have not appeared.

Genetic testing is appropriate for a person with definite or possible HHT, particularly when molecular confirmation will direct screening or family testing. It is also valuable when clinical findings overlap with another vascular syndrome, when the family diagnosis is uncertain, or when SMAD4-related juvenile polyposis-HHT is possible.

The highest-yield predictive test is targeted analysis for a known family variant. Once a pathogenic variant has been identified in an affected relative, children, siblings, and other at-risk relatives can be tested for that exact change. Relatives who test negative for a well-established familial variant can usually avoid HHT-specific surveillance, provided the family diagnosis and laboratory result are secure.

When no family variant is known, testing ideally begins with a person who clearly has HHT. Testing an unaffected relative first can produce an uninformative negative result because the laboratory does not know what variant to seek. A comprehensive panel generally includes ENG and ACVRL1, with SMAD4 analysis if the first genes are negative or as part of a simultaneous panel. Many laboratories include deletion/duplication analysis from the start.

Testing is also considered in a person with an apparently isolated pulmonary AVM, multiple cerebral vascular malformations, characteristic telangiectases, unexplained recurrent epistaxis plus family history, or juvenile polyposis with vascular features. The pretest probability and differential diagnosis determine whether an HHT-focused panel or a broader vascular-malformation panel is preferable.

Genetic counseling should address autosomal dominant inheritance, age-dependent symptoms, variable expression, the possibility of an uncertain result, and the medical value of identifying relatives early. Counseling is especially important for minors, prenatal or preimplantation questions, and SMAD4 results with cancer-surveillance implications.

How HHT Genetic Testing Is Performed

Testing usually uses blood, saliva, or a cheek-swab sample. Blood may be preferred when sample quality, mosaicism, or additional hematologic testing is relevant. DNA is extracted and analyzed by a clinical laboratory using sequencing and copy-number methods.

Sequence analysis detects many missense, nonsense, splice-site, and small insertion or deletion variants. Deletion/duplication analysis detects one or more missing or duplicated exons and larger gene-level changes. A laboratory that performs sequencing without validated copy-number analysis can miss a meaningful proportion of pathogenic variants.

A multigene panel can analyze ENG, ACVRL1, SMAD4, and selected overlapping genes together. The advantage is efficiency when the phenotype is not gene-specific. The disadvantage is a greater chance of finding variants of uncertain significance or findings in genes that do not fully match the clinical picture. The panel should be selected with a genetics professional or HHT center when possible.

Exome or genome sequencing may be considered after a negative high-quality panel in a family with compelling disease. These approaches can identify variants in newly recognized genes or regions not covered by a panel, but they do not guarantee a diagnosis. Some structural, regulatory, repetitive, or mosaic variants remain difficult to detect, and reanalysis may be useful as knowledge advances.

The report should list the gene, transcript, DNA and protein change, zygosity, classification, assay method, and limitations. Pathogenicity is assessed using population frequency, predicted and demonstrated effects on protein function, prior cases, segregation in families, and phenotype consistency. A finding should not be called disease-causing solely because it is rare.

Turnaround time varies by laboratory and urgency. The DNA result generally remains valid for life, but interpretation can change. Families should retain the full report rather than only a verbal summary. The exact variant is needed for targeted testing in relatives, and an old uncertain result may warrant periodic review.

Genetic testing does not replace baseline clinical screening while results are pending when HHT is strongly suspected. A person with possible pulmonary or cerebral AVMs should not delay appropriate evaluation solely to wait for molecular confirmation.

Interpreting Positive, Negative, and Uncertain Results

A pathogenic or likely pathogenic variant in ENG or ACVRL1 confirms a molecular diagnosis consistent with HHT in the appropriate clinical setting. The result supports organ screening, bleeding assessment, and targeted testing of relatives. It does not reveal whether a pulmonary or brain AVM is present and should not be used to rank one person’s risk solely from the gene name.

A pathogenic or likely pathogenic SMAD4 variant confirms a syndrome that can include both HHT and juvenile polyposis. The patient needs HHT-directed evaluation plus gastrointestinal surveillance and management appropriate to SMAD4-associated polyposis. Family testing must communicate both sets of implications.

A true negative familial test occurs when the exact pathogenic variant known in the family is absent. This is a highly informative result. The relative generally did not inherit the family’s HHT predisposition and can usually be released from HHT-specific screening, unless symptoms suggest a separate diagnosis or there is concern about an incorrect family attribution.

An uninformative negative panel is different. If no pathogenic variant is found in a person who clinically has HHT, the diagnosis may still be valid. Current testing does not identify every causal change, and another gene or technically difficult variant may be responsible. Clinical screening continues according to the phenotype and family history. Relatives cannot be cleared by testing for a variant that has not been found.

A variant of uncertain significance, or VUS, is not a confirmed cause. It should not be used by itself to diagnose an asymptomatic child, determine that a relative is safe, or justify irreversible treatment. Segregation studies may help: a laboratory or genetics team may test selected affected and unaffected relatives to see whether the variant tracks with disease. Even then, formal reclassification should come from qualified interpretation.

A likely benign or benign result does not explain HHT. Common polymorphisms may appear in raw data or consumer reports but should not be confused with pathogenic variants. Medical management should not be based on automated internet interpretation of an isolated change.

Mosaicism can complicate interpretation. A pathogenic variant present in only a proportion of cells may be detected at a low level or missed in saliva or blood, depending on its distribution and assay sensitivity. Mosaic disease may produce a milder or segmental phenotype, but specialist review is required before drawing conclusions.

Every result should be reconciled with the clinical diagnosis. A clearly pathogenic ENG result in a person with recurrent epistaxis and pulmonary AVMs is coherent. A rare missense change in someone without HHT features may be incidental or uncertain. Good interpretation asks whether the variant mechanism, family pattern, and vascular phenotype agree.

Screening After a Diagnosis

The purpose of diagnosing HHT early is to find treatable vascular malformations before they cause stroke, abscess, hemorrhage, heart failure, or severe anemia. Screening should be coordinated through an HHT center or clinicians familiar with current international guidelines whenever possible.

Pulmonary AVM screening is recommended for people with possible or confirmed HHT. Transthoracic contrast echocardiography, often called a bubble echocardiogram, is commonly used as the initial screening test because it is sensitive for right-to-left shunting. Chest computed tomography is used to define treatable lesions when screening is positive or when clinical circumstances require direct imaging. Pulmonary AVMs with suitable feeding arteries can often be treated by transcatheter embolization.

After embolization, imaging follow-up checks for persistence, reperfusion, or growth of untreated lesions. A negative childhood screen may need repetition as the child grows, and adults may require repeat evaluation according to local protocols, pregnancy plans, symptoms, and prior findings. New shortness of breath, cyanosis, neurologic symptoms, or a fall in oxygen saturation warrants assessment rather than waiting for a routine interval.

Brain vascular-malformation screening is generally performed with magnetic resonance imaging using an HHT-appropriate protocol. International practice differs regarding repeat imaging after a negative study, especially in adults, but initial screening is important because neurologic complications can occur without warning. Pediatric decisions should involve an HHT-experienced team and anesthesia planning when sedation is needed.

Liver vascular malformations may be assessed with Doppler ultrasound, computed tomography, or magnetic resonance imaging. Screening policies differ, but evaluation is particularly important when there are signs of high-output heart failure, abnormal liver tests, portal hypertension, biliary symptoms, pulmonary hypertension, or an abdominal bruit. Liver biopsy should generally be avoided when HHT vascular malformations are suspected because of bleeding risk.

All patients need periodic assessment for iron deficiency and anemia. A complete blood count and ferritin are commonly monitored in adults and in children with recurrent bleeding. Iron deficiency may be present even before hemoglobin falls. Gastrointestinal evaluation is considered when anemia is disproportionate to nosebleeds, fecal blood loss is suspected, or the person has a SMAD4 variant.

For people with pulmonary AVMs or an unresolved pulmonary shunt, preventive precautions may include meticulous avoidance of air in intravenous lines, antibiotic prophylaxis before procedures that can cause bacteremia according to HHT guidance, and avoidance of scuba diving. These precautions reduce risks created by loss of the lung capillary filter.

Managing Bleeding, Anemia, and Vascular Complications

Nosebleed management usually begins with humidification and moisturizing therapy to reduce mucosal dryness and trauma. Saline sprays or gels can be used regularly. People should learn first-aid measures such as leaning forward and applying firm pressure to the soft part of the nose. Severe, prolonged, or hemodynamically significant bleeding requires urgent care.

When local care is insufficient, an HHT-experienced ear, nose, and throat clinician may use laser, radiofrequency, electrosurgical, or other ablative treatment. Oral tranexamic acid can reduce bleeding for some patients but requires assessment of thrombotic history and contraindications. More severe disease may be treated with systemic antiangiogenic therapy, septodermoplasty, or surgical closure of the nostrils in carefully selected cases.

Iron replacement is central when chronic blood loss causes deficiency. Oral iron may be sufficient for mild or moderate depletion, but gastrointestinal side effects, poor absorption, and ongoing bleeding can limit response. Intravenous iron is used when oral therapy fails, rapid replacement is needed, or losses are substantial. Red-cell transfusion is reserved for severe anemia, acute blood loss, symptoms, pregnancy-related needs, or circumstances in which iron alone cannot restore oxygen-carrying capacity quickly enough.

Gastrointestinal telangiectases most often cause occult or chronic bleeding rather than dramatic hemorrhage. Endoscopic therapy can be helpful for selected lesions but may not be practical when abnormalities are diffuse. Systemic therapy may be considered for transfusion- or intravenous-iron-dependent bleeding. In SMAD4-related disease, polyp surveillance and removal follow a separate cancer-prevention strategy.

Pulmonary AVM embolization reduces right-to-left shunting and neurologic complication risk. It is not a genetic cure, and new or residual vessels may require follow-up. Brain vascular malformations are managed by a multidisciplinary neurovascular team; observation, microsurgery, embolization, or stereotactic radiosurgery may be considered according to lesion type and risk.

Symptomatic hepatic vascular malformations require specialist management. High-output cardiac failure may be treated with diuretics and correction of anemia, while systemic bevacizumab may be considered in severe cases at experienced centers. Liver transplantation is reserved for selected refractory complications. Embolization of hepatic arteries is generally avoided because it can cause catastrophic biliary or hepatic injury.

Anticoagulants and antiplatelet drugs are not automatically prohibited in HHT. When there is a strong indication—such as atrial fibrillation, venous thromboembolism, or a coronary stent—the benefit may outweigh bleeding risk. Decisions should be individualized, and bleeding control should be optimized rather than withholding necessary therapy solely because of the diagnosis.

Family Testing, Children, Pregnancy, and Long-Term Care

HHT is usually autosomal dominant. A person with a pathogenic variant has a 50% chance of passing it to each biological child, regardless of sex. The severity in a child cannot be predicted from the parent’s course. A mildly affected parent can have a child with a clinically important AVM, and the reverse is also possible.

Once the family variant is known, targeted testing can be offered at any age because the result has childhood medical utility. A child who tests positive should receive age-appropriate pulmonary and brain AVM screening and ongoing assessment for nosebleeds and iron deficiency. A child who tests negative for the familial variant can generally avoid repeated HHT surveillance.

When the familial variant is unknown, children at 50% risk are managed as potentially affected until HHT can be reasonably excluded. Clinical criteria alone are insufficient in early life. Families should receive an emergency and preventive plan that does not depend on visible telangiectases appearing first.

Pregnancy can increase blood volume and flow through vascular malformations. Ideally, a person with HHT should complete pulmonary AVM screening and treatment before conception. Someone who becomes pregnant without recent screening should be assessed by an HHT-experienced multidisciplinary team. Untreated significant pulmonary AVMs can cause maternal hypoxemia, hemorrhage, or paradoxical embolic complications.

Most people with HHT can have successful pregnancies, but risk stratification matters. Severe pulmonary hypertension, high-output cardiac failure, or complex vascular lesions may change counseling and delivery planning. Routine screening for spinal vascular malformations solely to permit epidural anesthesia is not generally required in asymptomatic patients, although anesthetic decisions remain individualized.

Reproductive options may include natural conception with prenatal diagnosis, in vitro fertilization with preimplantation genetic testing, donor gametes, or adoption. These are personal choices rather than medical obligations. A genetics professional can explain technical feasibility, timing, and limitations once the familial variant is known.

Long-term care works best with a shared record containing the exact variant, completed pulmonary and brain screening, embolization history, anemia and iron treatment, nosebleed severity, pregnancy considerations, antibiotic and intravenous-air precautions, and SMAD4 surveillance when applicable. Because HHT spans genetics, pulmonology, interventional radiology, neurology, hematology, otolaryngology, cardiology, gastroenterology, and obstetrics, fragmented care can leave important risks unaddressed.

A genetic diagnosis is valuable not because it forecasts every complication, but because it identifies who needs prevention. The result should lead to organized screening, practical bleeding care, treatment of iron deficiency, and timely testing of relatives—not to passive observation or fear.

References

Disclaimer

This article is for general education and does not replace evaluation by an HHT center, genetics professional, or other qualified clinician. Genetic results do not locate vascular malformations, and screening should not be delayed when HHT is strongly suspected. Sudden neurologic symptoms, severe breathlessness, coughing blood, or uncontrolled bleeding require urgent medical care.

RELATED ARTICLESMORE FROM AUTHOR